See more : Bemax Inc. (BMXC) Income Statement Analysis – Financial Results
Complete financial analysis of Elevai Labs, Inc. Common Stock (ELAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevai Labs, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- VDM Group Limited (VMG.AX) Income Statement Analysis – Financial Results
- NEWTECHWOOD CO (301588.SZ) Income Statement Analysis – Financial Results
- Shaanxi Beiyuan Chemical Industry Group Co., Ltd. (601568.SS) Income Statement Analysis – Financial Results
- RNI Negócios Imobiliários S.A. (RDNI3.SA) Income Statement Analysis – Financial Results
- Yip’s Chemical Holdings Limited (0408.HK) Income Statement Analysis – Financial Results
Elevai Labs, Inc. Common Stock (ELAB)
Industry: Biotechnology
Sector: Healthcare
About Elevai Labs, Inc. Common Stock
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.71M | 766.28K | 827.00 | 0.00 |
| Cost of Revenue | 578.02K | 324.00K | 2.85K | 0.00 |
| Gross Profit | 1.13M | 442.28K | -2.02K | 0.00 |
| Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
| Research & Development | 426.24K | 228.75K | 123.63K | 118.86K |
| General & Administrative | 3.37M | 1.54M | 602.73K | 95.94K |
| Selling & Marketing | 660.29K | 192.86K | 31.61K | 6.08K |
| SG&A | 4.03M | 1.80M | 633.96K | 102.99K |
| Other Expenses | -3.32M | -198.44K | -25.45K | 0.00 |
| Operating Expenses | 1.13M | 2.23M | 783.04K | 222.91K |
| Cost & Expenses | 5.47M | 2.55M | 785.89K | 222.91K |
| Interest Income | 5.56K | 7.70K | 0.00 | 0.00 |
| Interest Expense | 19.53K | 2.63K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.65K | 6.51K | 2.76K | 221.84K |
| EBITDA | -4.27M | -1.78M | -782.30K | -1.07K |
| EBITDA Ratio | -249.35% | -232.52% | -94,594.92% | 0.00% |
| Operating Income | -3.67M | -1.79M | -785.06K | -221.84K |
| Operating Income Ratio | -214.24% | -233.37% | -94,928.66% | 0.00% |
| Total Other Income/Expenses | -632.45K | -11.98K | 321.00 | -1.07K |
| Income Before Tax | -4.30M | -1.80M | -784.74K | -222.91K |
| Income Before Tax Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| Income Tax Expense | 0.00 | -2.00 | 3.00 | -1.07K |
| Net Income | -4.30M | -1.80M | -784.74K | -222.91K |
| Net Income Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| EPS | -0.40 | -0.19 | -0.05 | -0.05 |
| EPS Diluted | -0.40 | -0.19 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 10.75M | 9.53M | 17.33M | 4.41M |
| Weighted Avg Shares Out (Dil) | 10.75M | 9.53M | 17.33M | 4.41M |
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
ELEVAI Labs, Inc. Expands International Distribution into Europe
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
U.S. IPO Weekly Recap: IPO Market Sees A Little Activity In The Short Holiday Week
Source: https://incomestatements.info
Category: Stock Reports